Products State-of-the-Art Purification
AstreAdept® Nanofiber-based Cell and Gene Therapy Purification Technology
As cell and gene therapies become more accessible, new approaches are required to ensure the purity and volume of these novel therapeutics. Through our development of an unprecedented and proprietary nanofiber-based technology, we’re able to empower therapeutic innovators with the tools they need to purify the quantities they desire.
Our novel fiber technology enables:
-
Up to 10x increase in binding capacity
-
Faster processing times
-
Immediate access to binding surface area
-
Elimination of the need for long residence times
-
High flow rates
-
Higher process yields
Lab-scale purification of lentiviral particles in 5 easy steps
Shop Products
Nereus LentiHERO®
The Nereus LentiHERO® incorporates AstreAdept® technology to enable high recovery of purified lentiviral particles. This spin column device shortens the time to process multiple lab-scale lentiviral feedstocks, so reducing bottlenecks for viral vector sample preparation.
The Nereus LentiHERO® incorporates AstreAdept® technology to enable high recovery of purified lentiviral particles. This spin column device shortens the time to process multiple lab-scale lentiviral feedstocks, so reducing bottlenecks for viral vector sample preparation.
Key Features
- Labs-scale purification of lentiviral particles in 5 easy steps
- High binding capacity of 1.9E+10 lentiviral particles per unit
- >60% recovery of lentiviral particles, tested in serum-free feedstocks
- 95% reduction in HCP contamination
- Mild process and elution conditions
Shop Product
Shop Products
Nereus LentiHERO®
The Nereus LentiHERO® incorporates AstreAdept® technology to enable high recovery of purified lentiviral particles. This spin column device shortens the time to process multiple lab-scale lentiviral feedstocks, so reducing bottlenecks for viral vector sample preparation.
Key Features
- Labs-scale purification of lentiviral particles in 5 easy steps
- High binding capacity of 1.9E+10 lentiviral particles per unit
- >60% recovery of lentiviral particles, tested in serum-free feedstocks
- 95% reduction in HCP contamination
- Mild process and elution conditions